Anifrolumab-fnia Injection
Anifrolumab-fnia injection is a targeted biologic medicine used to treat moderate to severe systemic lupus erythematosus (SLE) in adults who are already on standard therapy.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Anifrolumab-fnia Injection: Patient Information Guide
A plain-language walkthrough of Anifrolumab-fnia Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Anifrolumab-fnia injection is approved for one condition across its supported product, Saphnelo:
- Saphnelo (intravenous or subcutaneous): Treatment of moderate to severe systemic lupus erythematosus (SLE) in adults who are already receiving standard therapy
- Saphnelo is not recommended for patients with severe active lupus nephritis (kidney inflammation from lupus) or severe active central nervous system lupus — effectiveness in these situations has not been established
⚙️How it works▾
Anifrolumab-fnia is a human monoclonal antibody — a precisely engineered protein — that locks onto a specific docking site on immune cells called the type I interferon receptor (IFNAR1). Type I interferons are immune signaling molecules that are overactive in most people with SLE, driving the inflammation that damages tissues and organs. By blocking this receptor and reducing the number of receptors available on the cell surface, Saphnelo turns down this inflammatory signal, quiets overactive immune responses, and helps normalize the immune cells that play a role in lupus flares.
💊How it's taken▾
Saphnelo comes in two delivery options that your doctor will choose based on your situation.
- Intravenous (IV) infusion: Administered by a healthcare provider over 30 minutes into a vein, once every 4 weeks. If a dose is missed, it should be given as soon as possible, with at least 14 days between infusions.
- Subcutaneous injection (Saphnelo prefilled syringe or SAPHNELO PEN autoinjector): Injected under the skin once every week. Patients or caregivers can give this at home after proper training. If a dose is missed, take it as soon as remembered, maintaining at least 3 days between injections.
There are no food restrictions with either form. Follow your prescriber's exact instructions; do not change the route or schedule on your own.
🤒Side effects — in detail▾
The most common side effects seen in clinical trials include:
- Upper respiratory tract infections, including cold symptoms and nasopharyngitis (runny nose/sore throat)
- Bronchitis
- Herpes zoster (shingles)
- Infusion-related reactions — headache, nausea, vomiting, fatigue, dizziness (IV route)
- Cough
- Respiratory tract infections
- Hypersensitivity (allergic) reactions
- Joint pain (arthralgia, reported after approval)
Seek medical help right away for signs of a serious infection, a widespread shingles outbreak, or any symptoms of a severe allergic reaction such as swelling of the face or throat, difficulty breathing, or feeling faint.
⚠️Warnings & precautions▾
- Serious and fatal infections: Saphnelo suppresses the immune system and has been linked to serious infections, including COVID-19 and pneumonia. Shingles (herpes zoster) — including severe, multi-area cases — occurs significantly more often with Saphnelo than with placebo. Do not start Saphnelo during an active infection.
- Severe allergic reactions: Anaphylaxis and angioedema have been reported. Saphnelo must be administered where these reactions can be treated immediately. Tell your doctor if you've ever had a severe allergic reaction to this drug — that is a contraindication.
- Cancer risk: As with other immunosuppressants, there is a potential risk of malignancy. The full impact is not yet known. Your doctor will weigh this before prescribing.
- Live vaccines: Do not receive live or live-attenuated vaccines while on Saphnelo. Get vaccinations up to date before starting treatment.
- Other biologics: Saphnelo should not be combined with other biologic therapies — this has not been studied and is not recommended.
🔀What it interacts with▾
Formal drug interaction studies have not been conducted with Saphnelo, but the label identifies important things to avoid or be careful with:
- Live or live-attenuated vaccines: Must be avoided during treatment — Saphnelo's immune-suppressing effect can make live vaccines dangerous or ineffective
- Other biologic therapies (including B-cell-targeted biologics): Not recommended in combination with Saphnelo — no safety data exist for this combination
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Active infection: Do not start Saphnelo until any significant active infection is resolved or adequately treated
- History of anaphylaxis to anifrolumab-fnia: This is a contraindication — Saphnelo must not be used
- Chronic or recurrent infections: Discuss risks and benefits carefully with your doctor before starting
- Known cancer risk factors or history of cancer: Your doctor should weigh the benefit-risk carefully
- Pregnancy: Limited human data exist; monoclonal antibodies like anifrolumab-fnia can cross the placenta, especially in the third trimester, potentially exposing the fetus. A pregnancy registry is available — contact AstraZeneca at 1-877-693-9268.
- Breastfeeding: It is unknown whether Saphnelo passes into human breast milk; discuss risks and benefits with your doctor
- Children: Safety and effectiveness in pediatric patients have not been established
- Adults 65 and older: Limited data are available; your doctor will assess appropriateness for your situation
- Vaccinations: Update all vaccines before starting; live vaccines must be avoided during treatment
📡Pharmacodynamics — effects in the body▾
After Saphnelo is administered, it substantially suppresses (by 80% or more) the activity of type I interferon-driven genes in the blood — an effect seen as early as week 4 and sustained through week 52 of treatment. This dampening of interferon activity returns to pre-treatment levels within 8 to 12 weeks after stopping the drug. In addition, patients with certain markers of active lupus — such as anti-dsDNA antibodies (proteins that attack DNA) or low complement levels (immune proteins that drop during flares) — showed measurable improvements in those markers over the course of treatment.
🔬Pharmacokinetics — how your body processes it▾
Anifrolumab-fnia is absorbed at about 73% when given by subcutaneous injection, and both the intravenous and subcutaneous routes reach steady-state blood levels in roughly 112 days (about 16 weeks). The drug is broken down by the body's normal protein-processing mechanisms — not by the liver — and it is cleared partly through a process driven by the very receptor it blocks (IFNAR1). After stopping Saphnelo, the drug becomes undetectable in the blood of most patients within about 16 weeks. No dose adjustments are needed based on age (18–70 years), sex, race, body weight, or mild-to-moderate kidney function changes.
📦How to store it▾
Store SAPHNELO in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze. stored at room temperature 68°F to 77°F (20°C to 25°C) for up to 7 days in the original carton to protect from light.
📄 Written from Anifrolumab-fnia Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Anifrolumab-fnia Injection
53 supplements and herbal products have documented interactions with Anifrolumab-fnia Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Moderate · 52
- Minor · 1
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Anifrolumab-fnia Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is Saphnelo and why has my doctor prescribed it for my lupus? ▾
How will I actually receive this medication — will I have to go to a clinic every time? ▾
What side effects should I expect, and which ones mean I need to call someone right away? ▾
Are there any vaccines or other medications I need to avoid while on Saphnelo? ▾
Is Saphnelo safe if I'm pregnant or thinking about getting pregnant? ▾
What happens if I miss a dose? ▾
Is Anifrolumab-fnia Injection available over the counter? ▾
When was Anifrolumab-fnia Injection first available? ▾
Who makes Anifrolumab-fnia Injection? ▾
💬 Answers drafted from Anifrolumab-fnia Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Anifrolumab-fnia Injection comes
Anifrolumab-fnia Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Saphnelo intravenous infusion is used to treat moderate to severe SLE in adults receiving standard therapy
- Saphnelo subcutaneous injection is used to treat moderate to severe SLE in adults receiving standard therapy
- Saphnelo is not recommended for severe active lupus nephritis or severe active central nervous system lupus, regardless of route
- Saphnelo intravenous: given by a healthcare provider as a 30-minute infusion into a vein, once every 4 weeks
- Saphnelo subcutaneous (prefilled syringe or SAPHNELO PEN autoinjector): injected under the skin once every week; patients may self-inject after training from a healthcare provider
- Saphnelo subcutaneous injections go into the thigh, abdomen (avoiding 2 inches around the navel), or upper arm (if a caregiver or healthcare professional gives the shot); rotate injection sites
- When switching between the intravenous and subcutaneous routes, follow your doctor's timing guidance — do not switch without instruction
📊 Anifrolumab-fnia Injection across the U.S. market
How Anifrolumab-fnia Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Anifrolumab-fnia Injection is used
A general measure of how commonly Anifrolumab-fnia Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Anifrolumab-fnia Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Anifrolumab-fnia Injection prescribed? Of the 1,594 medications we measure, Anifrolumab-fnia Injection ranks #932 by Medicaid prescriptions — more than 42% of them.
Utilization by Anifrolumab-fnia Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
2 ML anifrolumab-fnia 150 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2565280
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Anifrolumab-fnia Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 1 listed Anifrolumab-fnia Injection NDCs with Medicaid activity.
🔍 Compare Anifrolumab-fnia Injection products
A representative set of FDA-listed product records for Anifrolumab-fnia Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 300 mg/2 mL | — | AstraZeneca Nijmegen B.V. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 120 mg/0.8 mL | Subcutaneous | AstraZeneca Pharmaceuticals LP | BLA | View NDC → |
| 300 mg/2 mL | Intravenous | AstraZeneca Pharmaceuticals LP × 3 listings | BLA | View NDC → |
Showing 5 of 5 products — FDA National Drug Code Directory. See every product, package size and price: browse all 5 Anifrolumab-fnia Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Anifrolumab-fnia Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Anifrolumab-fnia Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Anifrolumab-fnia Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2565265 3 dose forms · 3 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2741468In current FDA listingsClinical drug / strength (SCD) 0.8 ML anifrolumab-fnia 150 MG/MLRxCUI 2741470 -
Dose form (SCDF) Injection RxCUI 2565279In current FDA listingsClinical drug / strength (SCD) 2 ML anifrolumab-fnia 150 MG/MLRxCUI 2565280 -
Dose form (SCDF) Prefilled Syringe RxCUI 2741476No current FDA listingClinical drug / strength (SCD) 0.8 ML anifrolumab-fnia 150 MG/MLRxCUI 2741478
Look up RxCUI 2565265 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Anifrolumab-fnia Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Anifrolumab-fnia Injection belongs to the Type I interferon Receptor Antagonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. AstraZeneca Pharmaceuticals LP is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.